Cerity Partners LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cerity Partners LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,060 shares of the biopharmaceutical company’s stock after acquiring an additional 512 shares during the quarter. Cerity Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $12,576,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of REGN. MML Investors Services LLC boosted its holdings in Regeneron Pharmaceuticals by 13.9% during the 3rd quarter. MML Investors Services LLC now owns 5,315 shares of the biopharmaceutical company’s stock valued at $5,587,000 after acquiring an additional 648 shares during the period. M&T Bank Corp boosted its holdings in Regeneron Pharmaceuticals by 4.3% during the 3rd quarter. M&T Bank Corp now owns 5,480 shares of the biopharmaceutical company’s stock valued at $5,761,000 after acquiring an additional 224 shares during the period. Coldstream Capital Management Inc. boosted its holdings in Regeneron Pharmaceuticals by 4.8% during the 3rd quarter. Coldstream Capital Management Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $1,359,000 after acquiring an additional 60 shares during the period. Toronto Dominion Bank boosted its holdings in Regeneron Pharmaceuticals by 2.6% during the 3rd quarter. Toronto Dominion Bank now owns 54,719 shares of the biopharmaceutical company’s stock valued at $57,523,000 after acquiring an additional 1,378 shares during the period. Finally, Soltis Investment Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 4.1% in the 3rd quarter. Soltis Investment Advisors LLC now owns 711 shares of the biopharmaceutical company’s stock worth $747,000 after buying an additional 28 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 3.6 %

Regeneron Pharmaceuticals stock opened at $576.72 on Thursday. The firm has a market cap of $63.05 billion, a price-to-earnings ratio of 15.07, a PEG ratio of 2.34 and a beta of 0.44. The stock has a fifty day simple moving average of $665.21 and a two-hundred day simple moving average of $762.01. Regeneron Pharmaceuticals, Inc. has a 12 month low of $525.99 and a 12 month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $11.86 EPS. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.61%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Wall Street Analyst Weigh In

Several research firms have weighed in on REGN. Citigroup dropped their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Robert W. Baird dropped their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. Wells Fargo & Company dropped their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Sanford C. Bernstein dropped their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Finally, Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $966.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.